Journal Basic Info

  • Impact Factor: 0.285**
  • H-Index: 6
  • ISSN: 2638-4558
  • DOI: 10.25107/2638-4558
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Cancer Clinic
  •  Ophthalmology
  •  Neurology
  •  Dermatology and Cosmetology
  •  Palliative Care
  •  Toxicology
  •  Family Medicine and Public Health
  •  Obstetrics and Gynecology

Abstract

Citation: Clin Case Rep Int. 2020;4(1):1147.DOI: 10.25107/2638-4558.1147

A Patient with BRAFV600E - Mutant Lung Adenocarcinoma Responding to Dabrafenib and Trametinib

Chloé Denis and Frédérique Bustin

Department of Oncology, University of Liège Hospital, Belgium Department of Pneumology, CHR de la Citadelle, Belgium

*Correspondance to: Chloé Denis 

 PDF  Full Text Case Report | Open Access

Abstract:

BRAF is a gene that encodes a protein belonging to the RAF family of protein kinases. This protein transduces signals via the mitogen-activated protein kinase pathway to the nucleus of receptive cells. We report another case of BRAFV600E-mutant lung adenocarcinoma responding to dabrafenib and trametinib treatment.

Keywords:

Cite the Article:

Denis C, Bustin F. A Patient with BRAFV600E - Mutant Lung Adenocarcinoma Responding to Dabrafenib and Trametinib. Clin Case Rep Int. 2020; 4: 1147.

Search Our Journal

Journal Indexed In

Articles with Grants

Gender Specificity in Obstructive Sleep Apnea and COVID-19: Putative Associations and Risk Factors
 Abstract  PDF  Full Text
Clinicopathological Characteristics of Medullary Thyroid Carcinoma with the Expression of Thyroglobulin in East – China
 Abstract  PDF  Full Text
View More...